Compare · NVO vs ONCO
NVO vs ONCO
Side-by-side comparison of Novo Nordisk A/S (NVO) and Onconetix Inc. (ONCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ONCO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $207.76B, about 80196.6x ONCO ($2.6M).
- Over the past year, NVO is down 13.6% and ONCO is down 99.6% - NVO leads by 85.9 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 6 for ONCO).
- NVO has more recent analyst coverage (25 ratings vs 0 for ONCO).
- Company
- Novo Nordisk A/S
- Onconetix Inc.
- Price
- $48.65+3.65%
- $0.65-0.72%
- Market cap
- $207.76B
- $2.6M
- 1M return
- -2.08%
- -22.69%
- 1Y return
- -13.63%
- -99.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 9
- 6
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ONCO
- SEC Form 10-Q filed by Onconetix Inc.
- SEC Form S-1 filed by Onconetix Inc.
- Realbotix Reports Financial Results for Q3-2026
- SEC Form 425 filed by Onconetix Inc.
- Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series
- Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
- Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Realbotix Corp. Provides Corporate Structure and Operations Update
- SEC Form 425 filed by Onconetix Inc.
- Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation